Schwab U.S. Dividend ETF Reconstitutes, Increases Healthcare Holdings
- Healthcare Stock Increase: The Schwab U.S. Dividend ETF's recent annual reconstitution added two healthcare stocks, raising the sector's allocation from 15.4% to 18.9%, making it the second-largest sector, indicating a strategic focus on the growth potential of healthcare.
- High-Yield Stock Selection: During this reconstitution, UnitedHealth and Abbott Laboratories were added to the top ten holdings with allocations of 4% and 3.95%, respectively, reflecting the fund's preference for high-yield healthcare stocks, which is expected to enhance long-term investor returns.
- Dividend Growth Potential: The new holdings have an average dividend growth rate of 9.4%, surpassing the pre-reconstitution rate of 8.6%, and while the overall yield remains at 3.4%, the faster growth rate could lead to higher total returns for investors in the future.
- Strong Dividend Records: Both UnitedHealth and Abbott have robust dividend growth histories, with the former increasing its dividend by 52% over the past five years and the latter by 40%, showcasing the attractiveness and stability of the healthcare sector in dividend investing.
Trade with 70% Backtested Accuracy
Analyst Views on MRK
About MRK
About the author
MERCK & CO INC - ENLICITIDE SAFETY PROFILE ALIGNS WITH PRIOR TRIALS, NO SIGNIFICANT VARIATIONS IN ADVERSE EVENTS
Safety Profile Consistency: The safety profile of Merck's product is consistent with previous trials, indicating no significant changes in adverse events.
No Meaningful Differences: There are no meaningful differences in adverse events reported compared to earlier studies, suggesting stability in safety outcomes.
MERCK & CO INC - FDA CHOOSES ENLICITIDE FOR COMMISSIONER'S NATIONAL PRIORITY VOUCHER IN DECEMBER 2025
Merck & Co. Announcement: Merck & Co. has selected Senlicitide for the position of Commissioner’s National Priority Voucher.
Vouchers Overview: The National Priority Voucher program is designed to incentivize the development of treatments for neglected diseases.
Merck & Co Inc's Enlicitide Lowers LDL-C by 64.6% After Eight Weeks from Baseline
- Merck & Co. Announcement: Merck & Co. has reported a significant reduction in LDL-C levels by 64.6% from baseline after eight weeks of treatment.
- Clinical Implications: This reduction indicates a potentially effective treatment option for managing cholesterol levels in patients.
Merck's Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Shows Greater LDL-C Reductions at Eight Weeks Compared to Recommended Oral Non-Statin Therapies When Used with Statins
Significant Findings: Merck's Senliciti demonstrated significantly greater LDL-C reductions at eight weeks compared to guideline-recommended oral non-statin therapies.
Study Context: The results were observed when Senliciti was added to background statin therapy, highlighting its potential effectiveness in cholesterol management.
MERCK & CO INC - WINREVAIR TO MOVE FORWARD INTO PHASE 3 REGISTRATION TRIAL FOR CPCPH-HFPEF
Merck's Advancement: Merck has made progress in advancing its COVID-19 treatment into the regulatory phase, specifically Phase 3 of its clinical program.
Focus on Treatment: The focus of this advancement is on the treatment of COVID-19, indicating ongoing efforts to combat the pandemic through effective therapies.
MERCK & CO: COMPREHENSIVE EVIDENCE FROM HEMODYNAMIC, FUNCTIONAL, ECHOCARDIOGRAPHIC, AND CLINICAL MEASURES BACKS FURTHER DEVELOPMENT OF WINREVAIR
Totality of Evidence: The article discusses the comprehensive evidence across various modalities, including hemodynamic, functional, echocardiographic, and clinical endpoints.
Support for Development: It emphasizes that this evidence supports the advancement of the WINRVAIR development program.
MERCK & CO INC - ENLICITIDE SAFETY PROFILE ALIGNS WITH PRIOR TRIALS, NO SIGNIFICANT VARIATIONS IN ADVERSE EVENTS
Safety Profile Consistency: The safety profile of Merck's product is consistent with previous trials, indicating no significant changes in adverse events.
No Meaningful Differences: There are no meaningful differences in adverse events reported compared to earlier studies, suggesting stability in safety outcomes.
MERCK & CO INC - FDA CHOOSES ENLICITIDE FOR COMMISSIONER'S NATIONAL PRIORITY VOUCHER IN DECEMBER 2025
Merck & Co. Announcement: Merck & Co. has selected Senlicitide for the position of Commissioner’s National Priority Voucher.
Vouchers Overview: The National Priority Voucher program is designed to incentivize the development of treatments for neglected diseases.
Merck & Co Inc's Enlicitide Lowers LDL-C by 64.6% After Eight Weeks from Baseline
- Merck & Co. Announcement: Merck & Co. has reported a significant reduction in LDL-C levels by 64.6% from baseline after eight weeks of treatment.
- Clinical Implications: This reduction indicates a potentially effective treatment option for managing cholesterol levels in patients.
Merck's Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Shows Greater LDL-C Reductions at Eight Weeks Compared to Recommended Oral Non-Statin Therapies When Used with Statins
Significant Findings: Merck's Senliciti demonstrated significantly greater LDL-C reductions at eight weeks compared to guideline-recommended oral non-statin therapies.
Study Context: The results were observed when Senliciti was added to background statin therapy, highlighting its potential effectiveness in cholesterol management.
MERCK & CO INC - WINREVAIR TO MOVE FORWARD INTO PHASE 3 REGISTRATION TRIAL FOR CPCPH-HFPEF
Merck's Advancement: Merck has made progress in advancing its COVID-19 treatment into the regulatory phase, specifically Phase 3 of its clinical program.
Focus on Treatment: The focus of this advancement is on the treatment of COVID-19, indicating ongoing efforts to combat the pandemic through effective therapies.
MERCK & CO: COMPREHENSIVE EVIDENCE FROM HEMODYNAMIC, FUNCTIONAL, ECHOCARDIOGRAPHIC, AND CLINICAL MEASURES BACKS FURTHER DEVELOPMENT OF WINREVAIR
Totality of Evidence: The article discusses the comprehensive evidence across various modalities, including hemodynamic, functional, echocardiographic, and clinical endpoints.
Support for Development: It emphasizes that this evidence supports the advancement of the WINRVAIR development program.
